Literature DB >> 9427251

Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine.

Y M Wang1, R R Gainetdinov, F Fumagalli, F Xu, S R Jones, C B Bock, G W Miller, R M Wightman, M G Caron.   

Abstract

Vesicular monoamine transporters are known to transport monoamines from the cytoplasm into secretory vesicles. We have used homologous recombination to generate mutant mice lacking the vesicular monoamine transporter 2 (VMAT2), the predominant form expressed in the brain. Newborn homozygotes die within a few days after birth, manifesting severely impaired monoamine storage and vesicular release. In heterozygous adult mice, extracellular striatal dopamine levels, as well as K+- and amphetamine-evoked dopamine release, are diminished. The observed changes in presynaptic homeostasis are accompanied by a pronounced supersensitivity of the mice to the locomotor effects of the dopamine agonist apomorphine, the psychostimulants cocaine and amphetamine, and ethanol. Importantly, VMAT2 heterozygous mice do not develop further sensitization to repeated cocaine administration. These observations stress the importance of VMAT2 in the maintenance of presynaptic function and suggest that these mice may provide an animal model for delineating the mechanisms of vesicular release, monoamine function, and postsynaptic sensitization associated with drug abuse.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9427251     DOI: 10.1016/s0896-6273(00)80419-5

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  113 in total

1.  Synaptic vesicle transporter expression regulates vesicle phenotype and quantal size.

Authors:  E N Pothos; K E Larsen; D E Krantz; Y Liu; J W Haycock; W Setlik; M D Gershon; R H Edwards; D Sulzer
Journal:  J Neurosci       Date:  2000-10-01       Impact factor: 6.167

Review 2.  The genetics of alcoholism and alcohol abuse.

Authors:  M A Enoch; D Goldman
Journal:  Curr Psychiatry Rep       Date:  2001-04       Impact factor: 5.285

Review 3.  VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse.

Authors:  Lee E Eiden; Eberhard Weihe
Journal:  Ann N Y Acad Sci       Date:  2011-01       Impact factor: 5.691

Review 4.  G protein-coupled receptor kinase/beta-arrestin systems and drugs of abuse: psychostimulant and opiate studies in knockout mice.

Authors:  Laura M Bohn; Raul R Gainetdinov; Marc G Caron
Journal:  Neuromolecular Med       Date:  2004       Impact factor: 3.843

Review 5.  Vesicular and plasma membrane transporters for neurotransmitters.

Authors:  Randy D Blakely; Robert H Edwards
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-02-01       Impact factor: 10.005

Review 6.  Monoamine oxidases in development.

Authors:  Chi Chiu Wang; Ellen Billett; Astrid Borchert; Hartmut Kuhn; Christoph Ufer
Journal:  Cell Mol Life Sci       Date:  2012-07-11       Impact factor: 9.261

7.  Noradrenergic control of cortico-striato-thalamic and mesolimbic cross-structural synchrony.

Authors:  Kafui Dzirasa; H Westley Phillips; Tatyana D Sotnikova; Ali Salahpour; Sunil Kumar; Raul R Gainetdinov; Marc G Caron; Miguel A L Nicolelis
Journal:  J Neurosci       Date:  2010-05-05       Impact factor: 6.167

8.  The Drosophila vesicular monoamine transporter reduces pesticide-induced loss of dopaminergic neurons.

Authors:  Hakeem O Lawal; Hui-Yun Chang; Ashley N Terrell; Elizabeth S Brooks; Dianne Pulido; Anne F Simon; David E Krantz
Journal:  Neurobiol Dis       Date:  2010-05-26       Impact factor: 5.996

Review 9.  Genetically engineered mouse models of Parkinson's disease.

Authors:  Donna M Crabtree; Jianhua Zhang
Journal:  Brain Res Bull       Date:  2011-08-03       Impact factor: 4.077

10.  Defunctionalized lobeline analogues: structure-activity of novel ligands for the vesicular monoamine transporter.

Authors:  Guangrong Zheng; Linda P Dwoskin; Agripina G Deaciuc; Seth D Norrholm; Peter A Crooks
Journal:  J Med Chem       Date:  2005-08-25       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.